Member Info for masterboffin

Yes, David Wilson from Avacta very positive summing up .”very confident”

I’ve never read a bulletin board with so many vague derampers . I accept that some traders will not be as bullish as most investors regarding the current share price but the general quality of deramping posts is poor . Please do better ladies and gents lol . Good luck to all genuine Avacta investors . Looking strong for continued growth .

Tragically , the Covid-19 situation is India is already out of control . The government has eased lock downs hoping to save the economy. But with a population of 1.3 billion the country is nowhere near its peak in terms of infections. Testing and medical care is poor. The country is believed to be nowhere near the peak of infections . Nobody can state accurately when infections will peak .With no effective lock down systems how can it ever stop infections ravaging the whole country?

"Delhi’s deputy chief minister, Manish Sisodia, has said the capital will have more than 500,000 Covid-19 cases by July and will need to increase the number of beds from 9,000 to 80,000 to meet demand. “For Delhi, this is a big problem if cases continue to rise,” Sisodia said."

https://www.theguardian.com/world/2020/jun/12/india-coronavirus-agony-i-did-everything-to-save-my-wife-and-baby

Winnifrith invariably takes a contrarian view by writing articles on his website , ************* , on popular stocks such as Avacta which have seen a big increase in share price (companies which are popular with investors ).He courts controversy by going against the grain of popular views and this naturally results in more interest in the articles he publishes on ************* out of morbid curiousity ! . The fact that we have a thread running on this board talking about him is evidence that his approach increases interest in his website .Plus of course to read all his articles on ************* it’s approximately £6 a month! Hence he has created a clever business model .

https://twitter.com/dswilsondx/status/1270684484564852743?s=21

Just tweeted by David Wilson #AVCT “looking forward to an interesting discussion “

"For me the first sign or rather a reminder of what AIM is, was the raise made when we were told there was to be none...simples. Most of you now wish to overlook that fact, which is fine."

Bladey , Avacta CEO did not not state there would be no fund raise . I recall the CEO stating in the webinar that Avacta are "fully funded". The CEO did not state in an RNS or Webinar there would be no fund raise. As MilkMONSTA has stated the recent fund raise is a smart strategic move because it strengthens even more the companies financial position and no longer leaves them vulnerable to a weak takeover bid IMHO.

It’s great to see the company being highlighted in a mainstream paper . Avacta is still “ under the radar” in terms of its full potential . Some folks argue we are in a Covid 19 investment bubble .That is certainly the case for a number of companies trying to cash in on the present climate . However , Avacta is a well established company with an excellent CEO plus quality directors/staff which offers investors and traders alike the opportunity to make life changing amounts of money plus the chance to support a company advancing medical science .

https://www.thisismoney.co.uk/money/investing/article-8362013/Mole-Valley-fund-house-launches-Yorkshire-T20-portfolio.html

One of the firms the T20 is investing in is biotech Avacta, which is working to develop an instant testing kit for Covid-19, in addition to a new class of cancer drugs aimed at patients who don't respond to existing therapies.

Avacta chief executive Alastair Smith says: 'I'm a Yorkshireman myself and many of our employees based at our Wetherby lab and head office are local, and it's great to have a showcase like this for the innovation and entrepreneurship going on in Yorkshire.'

Watching CNBC a few minutes ago . The New York stock exchange floor is being opened up for traders from today ( although not all companies are allowing their staff to return yet) . The president of the New York stock exchange was interviewed by Jim Cramer and co . The President of the exchange stated they will vett all trading staff before they enter the door by temperature checks and if that shows a high reading that staff member will have to undergo a covid 19 test . Cramer made the point that the temperature check will not identify asymptomatic persons and implied the stock exchange should consider using an instant covid 19 test !

https://www.dailymail.co.uk/health/article-8355617/Cell-receptors-increase-risk-coronavirus.html

Following on from Avacats's RNS dated 15th May (SARS-COVID-2-NEUTRALISING AFFIMERS) A topical article was published yesterday in the Daily Mail about the role of ACE2 cell receptors play in spreading COVID 19 . The virus attaches itself to the ACE2 receptors which then infect healthy cells. Article explains why certain groups of people e.g. obese are more at risk .

"The ACE2 receptor was found to be the main entry point for the potentially lethal severe acute respiratory syndrome (Sars) virus, of which this new coronavirus is the latest version. The receptors are found on cells in the nose lining, the lungs, pancreas, kidneys and gut, and in the lining of blood vessels, in the heart muscle and circulating on cells in the blood."

"The variety of locations could help explain why those people with Covid-19 have suffered such a wide range of different symptoms, from loss of a sense of taste and smell to stomach problems such as diarrhoea and post-infection heart problems.

No specific mention of Avacta in the article but the article is the same ballpark.........worth a read

https://masterinvestor.co.uk/evil-diaries/evil-knievil-autres-temps-autres-vies/

A interesting article published today . Simon Cawkwell AKA Evil Knievel is a well known commentator on financial markets and companies . Yes, he's prone to identify companies which he identifies as weak and will short the share price . However, if you read the article you will understand why he is a buyer of Avacta. A good read .

we are approaching 600 trades so far and we are only 20 minutes into the trading day. Huge investor interest in Avacta now.

https://www.sharesmagazine.co.uk/article/the-small-cap-biotech-stocks-making-200-returns-this-year

Shares magazine (published today))maintaining the view that Avacta is very much a buy.

"One of our favourite shares in the testing space is UK biotherapeutics company Avacta (AVCT:AIM) because we believe its rapid testing strip might prove to be a game-changer."

Watching CNBC now . The Brown University head being interviewed talking about the need for testing before they can reopen the university . She stated she “ had heard reports this week about rapid saliva testing “ . It made my ears prick-up . Huge demand for this product if Cytiva/Actava can nail it . I think they will .

For clarity ,Winnifrith has made no criticism of how Avacta is run . His critical observation was based purely on what he perceives to be the current value.I disagree with him as do may thousands of investors many of whom contribute to this BB . My own view is that the planet is experiencing unique circumstances and demand for our products will be huge .

Apologies for typos ...on iPhone !

I’ve listened to Tom Winnifrith’s bearcast this afternoon . He is obviously a marmite type character ie. people either like him or hate him . Personally , I find his opinion interesting . I also found that his views today on Avacta support my own view that Avacta’s share price has a long way further to go in an upward direction . He was basically putting forward the A contrarian view that on fundamentals , as a currently loss making company , Avacta is overvalued . It’s his modus operandi to take a critical look at companies . He actually stated that Avacta is a well run company but that it’s valuation of just under £200 million is inflated because it’s loss making . He didn’t go into the science and potential of the company which is why we shareholders believe it has a great future . TW also stated he would not be surprised to see Avavta’s share price go up in the present climate .

I caught the backend of that cnbc interview just now with an executive from a USA biotech company ( didn’t see the name of the company ). There’s no way their testing kit will compete with avacta . That company stated the test could only be analysed (spit sample) in a healthcare environment and costs $65 a piece !

Just tuned into BBC 1 news
. In the subject of testing one expert (I don’t know who she was because I only caught the backend of the report) stated that a rapid nasal or saliva test for covid-19 would be a “game changer” . If only a company could develop such a test ! Lol

Open Orphan merged with hvivo plc in January 2020 . Hvivo has a 49% joint venture interest in a private company (Imutex) . Imutex has developed a universal flu vaccine named Flu-v which is now phase 3 trial enabled . So , Open Orphan has a significant involvement / interest in a universal flu vaccine .